

Non-UCITS Retail Scheme Key Investor Information

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

MI Verbatim Portfolio 3 Fund - B Accumulation Shares; ISIN: GB00B3PSD118

MI Verbatim Portfolio 3 Fund a sub-fund of MI Verbatim Funds. The Fund is a non-UCITS retail scheme Open Ended Investment Company.

Apex Fundrock Ltd is the Authorised Corporate Director of the Fund ("MI" and "MI Funds" are trading names of the ACD).

Objectives and Investment Policy

The Fund will use a broadly defensive investment strategy with the aim of achieving capital growth over the medium to longer term.

The Fund will seek to achieve its objective through investment in collective investment schemes (regulated and unregulated) as well as directly held transferable securities, (including exchange traded notes), derivatives, cash, deposits, (including certificates of deposit), warrants, and money market instruments. Investment may be made globally but foreign currency exposure through non UK investments may be hedged back into Sterling.

The Fund may also gain exposure (directly and indirectly) to alternatives, including but not limited to, property, commodities, hedge funds, private equity, infrastructure and loans, through investment in collective investment schemes and transferable securities.

Use may also be made of stock lending, borrowing, cash holdings and derivatives. It is intended that derivatives will be used for investment purposes as well as for efficient portfolio management but the ACD does not anticipate that such use of derivatives will have any significant adverse effect on the risk profile of the Fund.

The Fund is actively managed without reference to any benchmark.

Other information:


Any income this share class generates will be reinvested to grow the value of your investment.

You can buy and sell shares on any business day in London. The base currency of the Fund is GBP.

Recommendation: Investment in the Fund should be regarded as long term, which is upwards of three to five years.

For full investment objectives and policy details please refer to the Prospectus.

Risk and Reward Profile



The Risk and Reward Indicator table demonstrates where the Fund ranks in terms of its potential risk and reward. The higher the rank the greater the potential reward but the greater the risk of losing money. The shaded area in the table above shows the Fund's ranking on the Risk and Reward Indicator.

Please note that even the lowest risk class can lose you money and that extreme market circumstances can mean you suffer severe losses in all cases.

This Fund is ranked this rating due to historical price movement of such investments. Please note the Fund's risk category may change in the future.

The indicator does not take into account the following risks of investing in this Fund:

Where the Fund makes investments in assets that are not denominated in GBP, changes in exchange rates will affect the value of your investment.

The Fund could lose money if an entity with which it interacts become unwilling or unable to meet its obligations to the Fund.

As an investor of another collective investment scheme, the Fund will bear, along with the other investors, its portion of the expenses of the other collective investment scheme, including management, performance and/or other fees. These fees will be in addition to the management fees and other expenses which a Fund bears directly with its own operations.

The Fund may invest in Exchange Traded Funds which represent a basket of securities that are traded on an exchange and may not necessarily trade at the net asset value of their underlying holdings. As a result, they may trade at a price that is above or below the value of the underlying portfolio.

Where the Fund invests in derivatives and forward transactions in the pursuit of the Fund's objective, the net asset value of the Fund may at times be volatile (in the absence of compensating investment techniques). However, it is the ACD's intention that the Fund will not have volatility over and above the general market volatility of the markets of the underlying investments and that the use of derivatives and forward transactions in the pursuit of the objective will not cause the risk profile to change.

The Fund is classed as a NURS and can have wider investment and borrowing powers than a UCITS scheme with higher investment limits in various areas. It can also invest to a greater extent in areas such as property and unregulated schemes and have the option to borrow on a permanent basis. Such additional powers can increase potential reward, but may also increase risk.

For further risk information please see the Prospectus.

Charges

The charges you pay are used to pay the costs of running the Fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off charges taken before or after you invest

Entry charge	0%
Exit charge	0%

These are the maximum charges that we might take out of your money before it is invested and before we pay out the sale proceeds of your investment. In some cases, you might pay less and you should speak to your financial advisor about this.

The ongoing charges figure is based on the annual expenses and may vary from year to year.

It excludes the costs of buying or selling assets for the Fund (unless these assets are shares of another fund).

For the ongoing charge, the figure is estimated at 28 February 2026. For more information about charges, please see the Prospectus.


Charges taken from the Fund over a year

Ongoing charges	1.47%
-----------------	-------

Charges taken from the Fund under certain specific conditions

Performance fee	None
-----------------	------

Past Performance



The share class was launched 15 February 2010.

The performance of the share class is calculated in: GBP

You should be aware that past performance is not a guide to future performance.

Fund launch date: 15 February 2010.

Practical Information

The document is issued by Apex Fundrock Ltd and contains information on the B Accumulation Shares only.

Each fund of the Company has its own pool of assets and liabilities, segregated by law. If one fund were unable to pay for its liabilities the assets of the other funds could not be used to pay for those liabilities.

You can get further detailed information regarding the Fund, including details of the investment manager and how to switch, buy and sell shares and other share classes available, within the prospectus, the supplementary information document and the annual and half yearly managers' reports. You can get these free of charge from Apex Fundrock Ltd, Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY or from our website: www.fundrock.com/mi-funds/. These are available in English only. You can also call us on 0345 872 4984 or email on Tatton@apexgroup.com for the latest share prices.

Details of the ACD's remuneration policy (including a description of how remuneration and benefits are calculated, the composition of the remuneration committee and the identities of persons responsible for awarding remuneration and benefits) are available at www.fundrock.com/mi-funds/ or by requesting a copy free of charge (see above for contact details).

The Depositary of the Fund is Citibank UK Limited.

Please note that the tax laws of the United Kingdom may impact your own tax position.

Apex Fundrock Ltd may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus for the Fund.

his Fund is authorised in the United Kingdom and regulated by the Financial Conduct Authority (FCA). Apex Fundrock Limited is authorised in the United Kingdom and regulated by the Financial Conduct Authority (FCA).

This Key Investor Information Document is accurate as of 28 February 2026.